Frank Mottola - Nov 14, 2023 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
SVP, Quality, GMP, Ops, IT
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Nov 14, 2023
Transactions value $
-$12,744
Form type
4
Date filed
11/16/2023, 05:00 PM
Previous filing
Mar 16, 2023
Next filing
Feb 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $18.5K +2K +41.74% $9.24 6.79K Nov 14, 2023 Direct F1
transaction SUPN Common Stock Sale -$31.2K -1.11K -16.35% $28.13 5.68K Nov 14, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -2K -100% $0.00* 0 Nov 14, 2023 Common Stock 2K $9.24 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes an aggregate of 343 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2 Represents the number of shares of common stock sold to cover the exercise price of the employee stock options.
F3 The option vested in four equal annual installments beginning on January 21, 2015.